Concenter BioPharma (Silkim Ltd.)
Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., focused on developing therapies targeting inflammatory processes involved in the pathogenesis of obesity and insulin resistance, with a focus on treating and preventing Type 2 Diabetes. The company has developed a protected platform of drugs based on extensive investigation of animal models of human diseases, aiming to offer proven treatments for multiple indications.
Industries
Nr. of Employees
small (1-50)
Concenter BioPharma (Silkim Ltd.)
Concenter BioPharma Ltd., Israel
Products
Platform of metal‑complex small‑molecule therapeutic candidates for metabolic and inflammatory indications
A family of chemically related small‑molecule drug candidates based on metal‑ligand complexes with demonstrated anti‑inflammatory and metal‑chelation activity, being developed for treatment and prevention of Type 2 Diabetes and other indications.
Platform of metal‑complex small‑molecule therapeutic candidates for metabolic and inflammatory indications
A family of chemically related small‑molecule drug candidates based on metal‑ligand complexes with demonstrated anti‑inflammatory and metal‑chelation activity, being developed for treatment and prevention of Type 2 Diabetes and other indications.
Services
Execution of early-stage clinical studies in collaboration with tertiary care centers, including patient screening, enrollment, on-site dosing, monitoring and data collection for metabolic disease endpoints.
In vivo pharmacology and safety studies across multiple animal models to evaluate therapeutic activity, tolerability and to support IND-enabling packages.
Support for preparing IND/CTA documentation, engaging in pre‑IND discussions and coordinating patent filings across jurisdictions.
Execution of early-stage clinical studies in collaboration with tertiary care centers, including patient screening, enrollment, on-site dosing, monitoring and data collection for metabolic disease endpoints.
In vivo pharmacology and safety studies across multiple animal models to evaluate therapeutic activity, tolerability and to support IND-enabling packages.
Support for preparing IND/CTA documentation, engaging in pre‑IND discussions and coordinating patent filings across jurisdictions.
Expertise Areas
- Platform drug discovery and development
- Type 2 Diabetes therapeutics and translational research
- Preclinical animal models and in vivo pharmacology
- Clinical trial design and operations for metabolic disease
Key Technologies
- Metal‑ion complex therapeutics (iron chelation and zinc delivery)
- Diet‑induced and disease‑specific animal models
- Subcutaneous injectable formulations
- Oral dosage form development
News & Updates
Concenter BioPharma, together with the SHEBA Medical Center in Israel, began recruiting patients for a clinical trial using Zygosid-50 to assess its safety and efficacy in treating Type 2 Diabetes.
The company is in the process of raising funds to support the clinical trial of Zygosid-50 for Type 2 Diabetes.
The company was recognized as the winner in the 'Best Specialty Drug Platform - Israel' category at the 2021 Biotechnology Awards.
The patent for Zycords, a family of new chemical entities, was granted by the European Patent Office and validated in major European countries.
An article discussing the development of a drug that could address the root cause of Type 2 Diabetes, developed by Concenter BioPharma.
An article about an Israeli team developing a new drug for treating insulin resistance in Type 2 Diabetes.
Concenter BioPharma, together with the SHEBA Medical Center in Israel, began recruiting patients for a clinical trial using Zygosid-50 to assess its safety and efficacy in treating Type 2 Diabetes.
The company is in the process of raising funds to support the clinical trial of Zygosid-50 for Type 2 Diabetes.
The company was recognized as the winner in the 'Best Specialty Drug Platform - Israel' category at the 2021 Biotechnology Awards.
The patent for Zycords, a family of new chemical entities, was granted by the European Patent Office and validated in major European countries.
An article discussing the development of a drug that could address the root cause of Type 2 Diabetes, developed by Concenter BioPharma.
An article about an Israeli team developing a new drug for treating insulin resistance in Type 2 Diabetes.